# Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Source: https://onco.cc/trials/nct07283835/  
OnCo record `nct07283835` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Cretostimogene grenadenorepvec in bladder & urothelial cancer, run by Lepu Biopharma Co., Ltd., now recruiting.

## Summary

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin is a phase 2 interventional study registered as NCT07283835 by Lepu Biopharma Co., Ltd., with 16 participants planned, started 2025-12-04 and due to reach its primary completion in 2027-12-31. Interventions recorded: Cretostimogene Grenadenorepvec.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07283835
- Phase: 2
- Setting: A Single-arm, Open-label, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of Cretostimogene Grenadenorepvec in Patients With BCG-unresponsive High-risk Non-Muscle Invasive Bladder Cancer
- Sponsor: Lepu Biopharma Co., Ltd.
- Enrolled: 16

## Sources

- ClinicalTrials.gov NCT07283835: https://clinicaltrials.gov/study/NCT07283835

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [Cretostimogene grenadenorepvec](https://onco.cc/drugs/cretostimogene/)
- companies: [Lepu Biopharma](https://onco.cc/companies/lepu-biopharma/)

---
JSON: https://onco.cc/api/v1/entities/nct07283835.json